AstraZeneca's Rilvegostomig Study Targets Advanced Solid Tumors with Subcutaneous Administration
AstraZeneca is investigating the pharmacokinetics and safety of subcutaneous rilvegostomig in adults with advanced solid tumors.
Asset / Drug
Drug and asset intelligence for immuno-oncology with 1 indexed intelligence signal across regulatory, clinical, competitive, and market developments.
No catalysts indexed for this entity yet.
No catalysts indexed for this entity yet.
No related entities indexed yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.